AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Article Link
Collect
Submit Manuscript
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Open Access

Research progress on the pathological mechanisms and clinical treatment of spinal cord ischemia–reperfusion injury

Xiao GuaQiwen BaoaJingtao PengaJishan Yuanb( )
School of Medicine, Jiangsu University, Zhenjiang 212001, Jiangsu, China
Department of Orthopedics, Zhenjiang First Peoples's Hospital, Zhenjiang 212002, Jiangsu, China
Show Author Information

Abstract

Background

Studies evaluating the pathophysiology of spinal cord ischemia–reperfusion injury (SCIRI) have produced targeted insights across multiple pathways. However, their clinical translation and therapeutic applicability remain limited.

Objective

This review synthesizes the recent advances in the understanding of SCIRI mechanisms and evaluates emerging therapeutic strategies, providing insights for future research and clinical translation.

Methods

Using “spinal cord ischemia–reperfusion injury” as the search term, we searched the relevant literature published in the China National Knowledge Infrastructure (CNKI) and PubMed databases. We included 74 articles in the review and analysis.

Results and conclusion

sSCIRI pathogenesis is a self-sustaining vicious cycle, progressing through acute, subacute, and chronic phases. Acutely, ischemia-induced mitochondrial dysfunction triggers excitatory amino acid release and calcium overload, which acts as a critical hub for downstream damage. Subacutely, these events initiate robust neuroinflammation and disrupt the blood–spinal cord barrier, facilitating inflammatory cell infiltration and exacerbating oxidative stress. Chronically, this interplay culminates in widespread neuronal programmed cell death and regeneration-inhibitory glial scar formation, leading to poor neurological outcomes.

Current treatments (e.g., glucocorticoids, hyperbaric oxygen) primarily target inflammation and oxidative stress, but they offer limited regenerative benefits. Strategies such as stem cell/exosome therapy, bioactive nanomaterials, and neuromodulation show preclinical potential in promoting axonal regeneration and modulating inhibitory microenvironments, yet clinical translation is hindered by scalability, safety, and delivery standardization.

Future efforts must prioritize the development of standardized animal models, combinatorial neuroregenerative approaches, and rigorous translational studies to bridge the gap between experimental findings and clinical efficacy in SCIRI treatment.

Graphical Abstract

References

【1】
【1】
 
 
Journal of Neurorestoratology

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Gu X, Bao Q, Peng J, et al. Research progress on the pathological mechanisms and clinical treatment of spinal cord ischemia–reperfusion injury. Journal of Neurorestoratology, 2026, 14(2). https://doi.org/10.1016/j.jnrt.2026.100275

341

Views

1

Crossref

1

Web of Science

0

Scopus

Received: 09 May 2025
Revised: 13 September 2025
Accepted: 17 October 2025
Published: 01 April 2026
© 2026 The Authors.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).